论文部分内容阅读
目的探讨与子宫内膜腺癌发病相关的临床病理因素。方法选取2009年1月-2015年5月在该院治疗的子宫内膜腺癌患者173例为研究对象,回顾性分析其临床资料、病理学结果、术前血清CA125结果,并分析患者雌激素受体(ER)、孕激素受体(PR)、细胞增殖核抗原(Ki-67)及抑癌基因(p53)的表达情况。结果 173例患者中,年龄<60岁、已绝经和无合并症的患者比例较高。年龄与肌层浸润深度相关(P<0.05),年龄越大肌层浸润深度越深;与肿瘤分化程度、手术-病理分期和子宫外转移无关(P>0.05)。绝经状态与肌层浸润深度和肿瘤分化程度相关(P均<0.05),与手术-病理分期和子宫外转移无关(P>0.05)。有无并发症与肌层浸润深度和子宫外转移相关(P均<0.05),与肿瘤分化程度和手术-病理分期无关(P>0.05)。ER、PR、p53及血清CA125水平均与肌层浸润深度、肿瘤分化程度、手术-病理分期和子宫外转移相关(P均<0.05);Ki-67与肌层浸润深度、肿瘤分化程度和手术-病理分期相关(P均<0.05),与子宫外转移无关(P>0.05)。结论年龄较小、未绝经患者子宫内膜腺癌发病率高,已绝经、有合并症患者子宫内膜腺癌恶性程度高。血清CA125、组织ER、PR、Ki-67和p53表达与子宫内膜腺癌的临床病理相关。
Objective To investigate the clinicopathological factors associated with the pathogenesis of endometrial adenocarcinoma. Methods A total of 173 patients with endometrial adenocarcinoma treated in our hospital from January 2009 to May 2015 were selected as the research object. The clinical data, pathological results, preoperative serum CA125 results were analyzed retrospectively. The estrogen Receptor (ER), progesterone receptor (PR), Ki-67 and p53. Results Of the 173 patients, those aged <60 years had higher rates of menopause and no complications. The age was related to the depth of myometrial invasion (P <0.05). The deeper the depth of myometrial invasion was, the higher the depth of myometrial invasion was. There was no correlation with the degree of tumor differentiation, surgical-pathological staging and extrauterine metastasis (P> 0.05). The menopausal status was related to the depth of myometrial invasion and tumor differentiation (all P <0.05), but not to the surgical-pathological stage and extrauterine metastasis (P> 0.05). The presence or absence of complications was related to the depth of myometrial invasion and extrauterine metastasis (all P <0.05), but not with the degree of tumor differentiation and the stage of surgery-pathology (P> 0.05). The levels of ER, PR, p53 and serum CA125 were correlated with the depth of myometrial invasion, tumor differentiation, surgical-pathological stage and extrauterine metastasis (all P <0.05). Ki-67 and myometrial invasion depth, - pathological stage (P <0.05), but not with extrauterine metastasis (P> 0.05). Conclusion There is a high incidence of endometrial adenocarcinoma in patients who are younger and not yet menopausal, and menopause is not uncommon. Patients with comorbidities have a high degree of malignancy of endometrial adenocarcinoma. Serum CA125, tissue ER, PR, Ki-67 and p53 expression and clinicopathological correlation of endometrial adenocarcinoma.